Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology.

Bissett SL, Wilkinson D, Tettmar KI, Jones N, Stanford E, Panicker G, Faust H, Borrow R, Soldan K, Unger ER, Dillner J, Minor P, Beddows S.

Clin Vaccine Immunol. 2012 Mar;19(3):449-51. doi: 10.1128/CVI.05641-11. Epub 2012 Jan 25.


Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.

Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Pal├╣ G.

Vaccine. 2014 Sep 15;32(41):5357-62. doi: 10.1016/j.vaccine.2014.07.014. Epub 2014 Jul 18.


Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.


Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Bissett SL, Draper E, Myers RE, Godi A, Beddows S.

Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15.


Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.

Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, Beddows S.

Vaccine. 2011 Nov 3;29(47):8585-90. doi: 10.1016/j.vaccine.2011.09.021. Epub 2011 Sep 21.


Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Scherpenisse M, Mollers M, Schepp RM, Meijer CJ, de Melker HE, Berbers GA, van der Klis FR.

Hum Vaccin Immunother. 2013 Feb;9(2):314-21. Epub 2012 Nov 13.


Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.

LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.

Vaccine. 2014 Oct 29;32(47):6303-11. doi: 10.1016/j.vaccine.2014.08.071. Epub 2014 Sep 16.


Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M.

BMC Infect Dis. 2014 Mar 3;14:120. doi: 10.1186/1471-2334-14-120.


Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.

Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Wang SS, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group.

Sex Transm Dis. 2010 Nov;37(11):706-14. doi: 10.1097/OLQ.0b013e3181e1a2c5.


Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A; Costa Rican Vaccine Trial Group.

J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62. doi: 10.1093/jnci/djq384. Epub 2010 Oct 13.


Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria.

Nakalembe M, Banura C, Namujju PB, Mirembe FM.

J Infect Dev Ctries. 2015 Feb 19;9(2):197-205. doi: 10.3855/jidc.5719.


Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.

Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, Berbers GA, van der Klis FR, Wulffraat NM.

Ann Rheum Dis. 2014 Aug;73(8):1500-7. doi: 10.1136/annrheumdis-2013-203429. Epub 2013 May 30.


HPV Serology Testing Confirms High HPV Immunisation Coverage in England.

Mesher D, Stanford E, White J, Findlow J, Warrington R, Das S, Pebody R, Borrow R, Soldan K.

PLoS One. 2016 Mar 9;11(3):e0150107. doi: 10.1371/journal.pone.0150107. eCollection 2016.


Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.

Wu T, Hu YM, Li J, Chu K, Huang SJ, Zhao H, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW, Wang Y, Zhu FC, Li CG, Zhang J, Xia NS.

Vaccine. 2015 Jul 31;33(32):3940-6. doi: 10.1016/j.vaccine.2015.06.052. Epub 2015 Jun 19.


Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.

Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE.

J Infect. 2015 Jul;71(1):61-73. doi: 10.1016/j.jinf.2015.02.005. Epub 2015 Feb 21. Review.


A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.

Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R.

PLoS One. 2015 Mar 19;10(3):e0120152. doi: 10.1371/journal.pone.0120152. eCollection 2015.


Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses.

Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J; Collaborative Study Participants.

Int J Cancer. 2006 Mar 15;118(6):1508-14.


Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.

Ahmed AI, Bissett SL, Beddows S.

Infect Genet Evol. 2013 Aug;18:151-9. doi: 10.1016/j.meegid.2013.05.013. Epub 2013 May 27.


Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.

Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G.

Vaccine. 2014 Jun 17;32(29):3694-705. doi: 10.1016/j.vaccine.2014.03.040. Epub 2014 Mar 25.

Supplemental Content

Support Center